Tango Therapeutics stock falls despite positive cancer trial data
Tango Therapeutics (TNGX) shares fell 6% despite positive Phase 1/2 trial data for vopimetostat and daraxonrasib in pancreatic cancer, showing an 82% response rate and 9-month progression-free survival of 88% in 22 patients. The combination was well-tolerated, with no dose-limiting toxicities. Tango plans a Phase 3 trial in 2027.
How this was made
The 30-second read
Why it matters
The trial showed high response rates but the market reacted negatively, suggesting skepticism about commercial translation.
Market read
First‑time disclosure of pivotal trial data; immediate price impact indicates traders should monitor upcoming Phase 3 plans.
What to watch
Potential partnership with Revolution Medicines and upcoming FDA discussions could mitigate short‑term concerns.
Background
Tango Therapeutics (NASDAQ:TNGX) presented new Phase 1/2 data for its PRMT5 inhibitor vopimetostat combined with Revolution Medicines' daraxonrasib in pancreatic cancer patients.
Ticker impact
Tango Therapeutics disclosed Phase 1/2 trial results showing an 82% response rate but the stock fell 6% on the news.
likely pressure as investors price in uncertainty about Phase 3 rollout and commercial viability
The article reports first‑time trial numbers; the immediate 6% decline shows the market is not convinced the data will translate into near‑term value.
Market effects
May temper enthusiasm for other early‑stage biotech trials in the PRMT5 inhibitor space.
Limited to U.S. biotech equities; no broader regional effect.
Low; relevance confined to specialty oncology investors.
Counterpoint
The data could be a catalyst for a longer‑term rally if the Phase 3 trial succeeds, making the short‑term dip a buying opportunity.
Key entities
- companyTango Therapeutics
Biotech firm developing PRMT5 inhibitors.
- companyRevolution Medicines
Partner providing the RAS(ON) inhibitor daraxonrasib.
